// App-Quantinova.ai

710.0 : Survival impact of CAPOX versus FOLFOX in the adjuvant treatment of stage III colon cancer.

Researchers

Presenter

  • Jonathan M. Loree

Principal Investigators

  • Aaron Sha

  • Maryam Soleimani

  • Maria Yi Ho

  • Hagen F. Kennecke

  • Winson Y. Cheung

  • Karen E. Mulder

  • Shirin Abadi

  • Jennifer L. Spratlin

  • Sharlene Gill

Medical Centers

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • BC Cancer Agency, Vancouver, BC, Canada

  • University of Alberta, Edmonton, AB, Canada

  • Cross Cancer Institute, Edmonton, AB, Canada

  • Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada

  • Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • mFOLFOX6

  • Capecitabine + Oxaliplatin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved